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[B The present invention relates to a diagnostic nuclear medicine. More speci?cally, the present invention re lates to tumor imaging utilizing radioactive gallium. '
Description of the Prior Art
Gallium-67, as the carrier-free citrate,-is used rou tinely in clinical medicine in the diagnosis, staging and monitoring of several neoplastic disease states (Semin Nucl Med 6: 331-334, 1976) . Unfortunately, this agent is plagued with imaging problems which are related to plasma protein binding. Speci?cally, gallium 'has an affinity for blood and soft tissue proteins, and when given in very low doses, is extensively bound (J Phar macol Exp I71erapeut 168: 193-198, 1973) . Gallium also has an affinity for tumors (Science 167:289-290, 1970; J Nucl Med 10: 103-105, 1969) and abscesses (J Nucl Med 21: 484-488, 1980) . After intravenous administration, ' gallium activity in tumors is seen immediately and reaches a maximum within eighteen hours (Semin Nucl Med 8: 193-203, 1978) . Biologic clearing of gallium from blood and soft tissue binding sites is a slow pro cess, and results in the presence of image obscuring activity long after the ideal imaging time. Three major consequences of this binding phenomenon are: (a) it is necessary to delay imaging procedures for long periods of time (48-72 hours) to allow for the clearance of non productive radioactivity; (b) the long waiting period allows the build-up of image obscuring activity in the intestinal tract due to secretion of gallium into the large bowel (J Nucl Med 14: 208-214, 1973) ; and (0) pro longed retention of large quantities of 676a in the body results in a relatively high radiation dose (J Nucl Med 12: 755-756, 1973 ).
Several reports have described methods or agents which attempt to enhance the process of imaging a tumor or abscess by shortening the biologic half life of carrier-free gallium-67 citrate. Generally, these fall into two categories: (a) agents which compete with radioac tive gallium for blood and tissue binding sites, thus releasing the radioactive metal ion making it available for kidney elimination; 'or (b) complexing'or chelating ' agents which compete with blood and tissue binding sites for free gallium, forming a complex which is rap idly cleared by the kidney.
The initial work took the ?rst approach and used a group (IIB) metal complex (Scandium citrate) as a se lective competitive binding agent (South Med J 66: 1339 -1340 , 1973 JNucI Med 21: 361-365, 1980) . Scan dium, by occupying gallium binding sites on blood pro teins, prevents the accumulation of gallium on'these sites. Scandium appears to have little or no effect upon gallium binding in tumors. When used in animal studies, where gallium-67 and scandium citrates were injected simultaneously, extremely high tumor to blood and tumor to tissue ratios were obtained. Unfortunately, scandium produces a severe hemolytic anemia when administered to man (South Med J 66: 1339 -1340 , 1973 J Nucl Med 21: 361-365, 1980) . The use of iron dextran in similar fashion to clear gallium from rabbits bearing induced abscesses resulted in the clearing of gallium with enhanced abscess uptake of gallium (J Nucl Med 17: 356-358, 1976 shown that relatively large doses of non-radioactive gallium will decrease blood activity without signi? cantly reducing tumor activity (J Nucl Med 20: 656, 1979; Invest Radiol 14: 482-492, 1979) . Several investigators have used the second approach, employing a chelating agent, desferoxamine, to reduce gallium blood activity (J Nucl Med 21: 421-425, 1980; J Nucl Med 20: 248-251, 1979; Radiology 131: 775-779, 1979; Radiolog 130: 241-244, 1979) . The resulting gal lium desferoxamine complex is eliminated via the kid ney at a rate greater than that observed for gallium alone. Unfortunately, this clearing agent must be admin istered 24 hours after the gallium injection in order to minimize loss of tumor activity.
SUMMARY OF THE INVENTION It is, therefore, a primary object of the present inven tion to provide improved radiopharmaceutical compo sitions and methods for tumor imaging which overcome or reduce the above mentioned problems of the prior art.
Carrier-free solutions of gallium-67 citrate were ad ministered to normal and tumored rats, and blood levels of radioactivity were monitored as a function of time.
Metal complexes of aluminum, gallium, indium or thal lium were administered at times varying from two to six hours following the injection of the radiopharmaceuti cal. In the cases of indium and gallium, the blood activ ity was observed to decrease very rapidly, and a gener alized clearing of soft tissue activity was observed. Sim ilar studies using imaging techniques, reveal that activ ity bound within tumors is obviously affected by the addition of moderate doses of carrier gallium. When indium citrate was administered two hours after the radiopharmaceutical the tumor activity increased sig ni?cantly. When carrier-free gallium-67 was adminis tered simultaneously with indium citrate, the biodistri bution of gallium in rats bearing transplanted tumors (lymphoma and hepatoma) was found to be dramati cally altered. Two hours after dosing, radioactivity is observed in the kidney, bladder, bone and tumor. Other areas and tissues were essentially void of activity. This rapid clearance of non-productive gallium from diffmse soft tissues, blood and organs such as liver, lung and spleen demonstrates the potential for use of the gallium 68 coupled with emission tomography.
Therefore, in accordance with the present invention, it has been discovered that intravenous injection or' a non-radioactive indium complex simultaneously with, shortly before or shortly after, the intravenous injection of carrier free gal1ium-67(67Ga) or gallium-68(68G:e), alters the biodistribution of the radioactive gallium. More speci?cally, the indium complex occupies ncm tumor gallium receptor sites, and, therefore, the gallium will not be retained on these receptor sites to thereby obscure the imaging process. In other words, the an dium complex has a high affinity for non-tumor galliuun receptor sites leaving the gallium free to be bound to tine tumor gallium receptor sites. It has been shown that indium complexes alter gailii um-67 biodistribution in rats bearing transplanted tu mors (lymphoma and hepatoma).
The indium and gallium complexes may be adminns tered by injection, with intravenous injection beirng preferred. The gallium complexes must be administered Radiopharmaceutical compositions may be prepared by dissolving the gallium and/or indium complex in any acceptable solvent such as water, normal saline, buffer normal to the pharmaceutical preparation, and mixtures thereof. Normal saline is preferred as a solvent.
It is preferred to administer the gallium and the in dium simultaneously, however, the indium may be ad ministered before or after the gallium, preferably within 2 hours before or after the gallium. '
When gallium and indium are administered in accor dance with the present invention the following advan tages are realized: the time required for image obscuring blood and/or soft tissue radioactivity to clear the body, enabling one to obtain a clear image of the tumor, is reduced; the radiation dose to the patient is reduced by increasing the rate at which the radioactive gallium clears the body; and the short-lived position emitting gallium-68 isotope may be recorded by emission tomo graphic imaging equipment to thereby allow viewing of the tumor in three dimensions. The radioactive gallium may be measured by using external scintigraphic tech niques (either photon or positron). Gallium citratesolutions were prepared by a method similar to that disclosed in J Am Chem -Soc 72: [3822] [3823] 1950 . Gallium nitrate (375 mg) was dis solved in a minimum volume of boiling concentrated hydrochloric acid, citric acid solution (20% w/v, 2.5 ml) was added thereto, the resulting solution cooled to room temperature and neutralized with sodium hydrox ide solution (?nal concentration: Ga 15 mg/ml-ZO mg citrate/ml, pH 7.4). In a similar manner, indium citrate was prepared (?nal concentration: In 6.67 mg/ml-ZO mg citrate/ml). Aqueous solutions of aluminum lactate [189] [190] 1978) . The right external jugular vein was then exposed and cannu lated asan injection site. The animal was placed in a lead cradle and the blood loop inserted into the shielded well of a sodium iodide.thallium crystal. The animal received an injection of carrier-free gallium citrate (100-120 uCi) via the jugular cannula. Blood activity within the loop was continuously monitored as a func tion of time using a Packard Model 9012 Multi-channel Analyzer/Multi-scaler system (Packard Instrument Co., Downersville, 11].). Six hours post injection, the animal received a second injection containing one of the clearing agents (=72 mmole/Kg). In subsequent experi ments, clearing agents were administered two hours after or simultaneously with the radioactive dose.
Initial studies used non-tumored male Sprague Daw ley rats weighing between 250 and 300 grams. Subse quent studies in tumored rats used male Buffalo rats is characterized by a rapid distribution phase followed by a slower elimination phase. The rapid distribution process appears to be complete four to six hours after dosing and is in itself multiplastic. There is a very rapid component (t; = 12 seconds) which may be due to kid ney elimination of the citrate complex. This process would become insigni?cant as gallium complexed with citrate is transferred to binding sites on blood proteins, thus becoming less available for kidney elimination.
The effect of a relatively large dose of non-radioac tive gallium (3.3 mg/Kg) given six hours after the initial injection is seen in FIG. 1B . There is a dramatic, rapid drop in blood activity (approximately 40% of the blood activity is removed). This is followed by a rise in blood activity, possibly due to release of 67Ga from less avail able gallium stores by an isotopic exchange process. The rise in blood activity peaks 1.5 to 2 hours after the second injection and subsequent gallium elimination parallels that observed when no clearing agent is used. When gallium is administered in this manner, the blood activity measured eight hours post radiopharmaceutical dosing, is approximately 25% less than that observed when no clearing agent is given.
In similar experiments, equimolar quantities of non radioactive aluminum, indium, or thallium complexes were injected six hours after the carrier-free gallium dose. The results of these studies are summarized in There was no change in blood activity following a dose of 7.2 mmoles/Kg of thallium triacetate. Aluminum lactate caused a reduction of 9% in blood activity fol lowed by a 3% rise in activity. The net reduction in blood activity was only 6%. Indium chloride proved to be the most potent of the clearing agents tested. As was the case with non-radioactive gallium, indium chloride (FIG. 1C) caused a rapid drop in blood activity (85%) followed by an increase which peaked 1.5 to 2 hours after the clearing dose was given. The net reduction in blood activity was 60%. When indium citrate was used in similar fashion, the blood curve was observed to fall 77% and there was no signi?cant rise in blood activity (FIG. 1D) . The distributional difference between in dium chloride and indium citrate could be explained if citrate offered a weak, transient binding for that gallium which is displaced from the blood protein binding sites now occupied by indium. The gallium citrate complex thus formed must be rapidly cleared by the kidney. This is the same mechanism suggested above for the rapid drop in blood activity seen at early times. In the absence of citrate, gallium would seek alternate, non-vascular, binding sites (probably surface proteins in tissues) from which it would undergo a slower redistribution to blood sites vacated as indium undergoes distribution processes.
The two most successful clearing agents, gallium and indium citrate, were furher investigated to determine if varying the length of time between radiopharmaceuti cal dosing and clearing agent dosing altered the results. Gallium (3.3 mg/Kg) cleared 78% of the blood activity when given at two hours after the radiopharmaceutical. This was followed by the characteristic rise in activity which resulted in a net clearance of 70%. Indium citrate reduced the blood activity by 78% and no subsequent rise in activity was observed. '
Preliminary imaging studies performed in non tumored rats injected with one of the four clearing agents six hours post dosing, gave results which gener ally paralleled the blood studies. Injections of thallium or aluminum yielded no signi?cant redistribution of the radioactivity. Injections of non-radioactive gallium or indium citrate shifted the radioactivity out of the blood/soft tissue regions and into the kidneys and the bladder (FIG. 2) .
Clearing studies were performed on tumored rats using these agents in dosages suggested as optimal in both blood and preliminary imaging studies. Indium citrate was dosed at the level of 2.1 mg/Kg, and gallium citrate was dosed at 3 mg/Kg and 15 mg/Kg. "'hen given six hours after the initial injection, the high dose of non-radioactive gallium resulted in obvious redistri butions of radioactivity which would have obscured chest and abdominal images (i.e. liver, spleen, lung and intestine). However, tumor activity was observed to decrease. The lower dose of gallium generally has a less dramatic effect in that a great deal of activity remains in the 'abdomen, particularly in those organs with high reticuloendothelial (RE) activity (liver and spleen). 
